Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma

被引：0
|
作者：
Sznol, Mario [1 ,2 ]
Callahan, Margaret K. [3 ]
Kluger, Harriet [1 ,2 ]
Postow, Michael A. [3 ,4 ]
Gordan, RuthAnn [3 ]
Segal, Neil H. [3 ]
Rizvi, Naiyer A. [3 ]
Lesokhin, Alexander [3 ]
Atkins, Michael B. [5 ]
Kirkwood, John M. [6 ]
Burke, Matthew M. [1 ,2 ]
Ralabate, Amanda [1 ,2 ]
Rivera, Angel [1 ,2 ]
Kronenberg, Stephanie A. [3 ]
Agunwamba, Blessing [3 ]
Ruisi, Mary [7 ]
Horak, Christine [8 ]
Jiang, Joel [7 ]
Wolchok, Jedd [3 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale New Haven Med Ctr, Smilow Canc Ctr, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[6] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
O4
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
    Lebbe, C.
    Meyer, N.
    Mortier, L.
    Marquez-Rodas, I.
    Robert, C.
    Rutkowski, P.
    Menzies, A. M.
    Eigentler, T.
    Ascierto, P. A.
    Smylie, M.
    Ajaz, M.
    Svane, I-M.
    Gonzalez, R.
    Rollin, L.
    Saci, A.
    Grigoryeva, E.
    Pigozzo, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 737 - 737
  • [42] Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).
    Ascierto, Paolo Antonio
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Haanen, John B. A. G.
    Espinosa, Enrique
    Guren, Tormod Kyrre
    Munoz-Couselo, Eva
    Rorive, Andree
    Rutkowski, Piotr
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Hermann, Frank
    Jiang, Joel
    Schadendorf, Dirk
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase II study (CheckMate 069)
    Abernethy, Amy Pickar
    Postow, Michael Andrew
    Chesney, Jason Alan
    Grossmann, Kenneth F.
    Taylor, Fiona
    Coon, Cheryl
    Gilloteau, Isabelle
    Dastani, Homa
    Gagnier, Paul
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] (Neo-)adjuvant ipilimumab plus nivolumab (IPI plus NIVO) in palpable stage 3 melanoma - updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses
    Rozeman, E. A.
    Fanchi, L.
    van Akkooi, A. C. J.
    Kvistborg, P.
    Thienen, J. V.
    Stegenga, B.
    Lamon, B.
    Haanen, J. B.
    Schumacher, T. N. M.
    Blank, C. U.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
    Long, Georgina V.
    Atkinson, Victoria
    Lo, Serigne
    Guminski, Alexander David
    Sandhu, Shahneen Kaur
    Brown, Michael Paul
    Gonzalez, Maria
    Scolyer, Richard A.
    Emmett, Louise
    McArthur, Grant A.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] COST-EFFECTIVENESS OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) COMPARED WITH NIVO AND IPI MONOTHERAPIES IN THE FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN THE UNITED STATES: ANALYSIS USING 28-MONTH OVERALL SURVIVAL (OS) DATA FROM CHECKMATE 067
    Baker, T.
    Paly, V. F.
    Sabater, J.
    Gupte-Singh, K.
    Beyhaghi, H.
    Kotapati, S.
    Rao, S.
    Briggs, A.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [47] Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD)
    Schadendorf, Dirk
    Tawbi, Hussein A.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo Antonio
    Larkin, James
    Lao, Christopher D.
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Moshyk, Andriy
    Horton, Viviana Garcia
    Zhou, Jenny
    Xin, Yiqiao
    Palaia, Jennell
    McDonald, Laura
    Keidel, Sarah
    Salvatore, Anthony
    Sakkal, Leon A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
    Blank, Christian U.
    Reijers, Irene L. M.
    Pennington, Thomas
    Versluis, Judith M.
    Saw, Robyn P. M.
    Rozeman, Elisa A.
    Kapiteijn, Ellen
    Van der Veldt, Astrid Aplonia Maria
    Suijkerbuijk, Karijn
    Hospers, Geke
    Klop, W. Martin. C.
    Sikorska, Karolina
    Van der Hage, Jos A.
    Grunhagen, Dirk J.
    Spillane, Andrew
    Rawson, Robert V.
    Van de Wiel, Bart A.
    Menzies, Alexander M.
    Christopher, Alexander
    Van Akkooi, Jonathan
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
    Kluger, H.
    Sznol, M.
    Callahan, M.
    Postow, M.
    Gordon, R.
    Segal, N. H.
    Rizvi, N.
    Lesokhin, A.
    Atkins, M. B.
    Kirkwood, J.
    Burke, M.
    Ralabate, A.
    Rivera, A.
    Kronenberg, S.
    Agunwamba, B. U.
    Feely, W.
    Hong, Q.
    Krishnan, S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [50] CheckMate-032: Phase I/II open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC)
    Janjigian, Yelena Yuriy
    Bendell, Johanna C.
    Calvo, Emiliano
    Kim, Joseph W.
    Ascierto, Paolo Antonio
    Sharma, Padmanee
    Ott, Patrick Alexander
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    De Braud, Filippo G.
    Chau, Ian
    Tschaika, Marina
    Harbison, Christopher T.
    Lin, Chen-Sheng
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345